Imaging Biometrics secures U.S. healthcare system contract

Imaging Biometrics Limited has secured a contract with a U.S. healthcare organization to provide its brain tumor imaging software platform. The company's U.S. subsidiary signed an annual subscription agreement that includes three software products: IB Neuro, IB Delta T1, and IB FTBx. These software solutions analyze MRI scans to generate imaging biomarkers, which measure tumor characteristics and help clinicians make treatment decisions.

The platform aims to standardize the assessment of tumor physiology and treatment response, addressing key challenges in brain tumor management. Imaging Biometrics LLC CEO Michael Schmainda noted that the adoption of quantitative imaging biomarkers in neuro-oncology is reflected in this implementation. Trevor Brown, CEO of Imaging Biometrics Limited, mentioned that this is the second major installation for the company's software this quarter. The healthcare system's name and the financial terms of the agreement were not disclosed.